Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tilrekimig - Pfizer

Next Previous
Drug Profile

Tilrekimig - Pfizer

Alternative Names: anti-IL4/13/TSLP - Pfizer; PF-07275315

Latest Information Update: 01 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antiasthmatics; Skin disorder therapies
  • Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 4 receptor antagonists; Thymic stromal lymphopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Chronic obstructive pulmonary disease
  • Phase II Asthma; Atopic dermatitis

Most Recent Events

  • 28 Aug 2026 Pfizer plans a phase I pharmacokinetic trial in (In volunteers) in US in August 2026 (SC) (NCT07792941)
  • 24 Aug 2026 Pfizer plans a phase III trial for Atopic dermatitis (In Adolescents, In adults, In the elderly) in USA (SC) in August 2026 (NCT07783425)
  • 24 Aug 2026 Pfizer plans a long-term extension study C4531008 for Atopic dermatitis (SC) (NCT07783425) (NCT07765888)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top